$ALT
Altimmune, Inc.

2014 Q2 Form 10-Q Financial Statement

#000114420414028677 Filed on May 08, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2014 Q1 2013 Q1
Revenue $676.00 $3.740M $6.480M
YoY Change -59.18% -42.28% 5.37%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.420M $2.680M $2.280M
YoY Change 3.86% 17.54% -22.71%
% of Gross Profit
Research & Development $2.373M $3.427M $5.233M
YoY Change -30.27% -34.52% 11.22%
% of Gross Profit
Depreciation & Amortization $36.21K $39.94K $52.60K
YoY Change -13.49% -24.07% -41.55%
% of Gross Profit
Operating Expenses $4.829M $6.144M $7.566M
YoY Change -16.42% -18.79% -2.25%
Operating Profit -$1.170M -$2.402M -$1.091M
YoY Change -21.05% 120.21% -31.43%
Interest Expense $56.55K $69.87K $99.79K
YoY Change -43.46% -29.98% 3195.61%
% of Operating Profit
Other Income/Expense, Net $724.1K $173.1K -$1.011M
YoY Change 182.22% -117.13% 7.68%
Pretax Income -$445.8K -$2.229M -$2.102M
YoY Change -63.61% 6.05% -16.91%
Income Tax -$10.00K $30.00K $9.743K
% Of Pretax Income
Net Earnings -$439.1K -$2.258M -$2.111M
YoY Change -64.48% 6.96% -21.21%
Net Earnings / Revenue -64958.58% -60.39% -32.58%
Basic Earnings Per Share -$0.01 -$0.04 -$0.04
Diluted Earnings Per Share -$0.01 -$0.04 -$0.04
COMMON SHARES
Basic Shares Outstanding 54.48M shares 53.04M shares 48.37M
Diluted Shares Outstanding 53.04M shares

Balance Sheet

Concept 2014 Q2 2014 Q1 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.30M $9.500M $12.90M
YoY Change -28.48% -26.36% -15.69%
Cash & Equivalents $11.27M $9.535M $12.87M
Short-Term Investments $6.400M $6.400M
Other Short-Term Assets $600.0K $400.0K $600.0K
YoY Change -14.29% -33.33% -25.0%
Inventory
Prepaid Expenses
Receivables $600.0K $1.600M $5.600M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $12.43M $11.59M $19.07M
YoY Change -42.68% -39.24% -11.43%
LONG-TERM ASSETS
Property, Plant & Equipment $386.5K $380.6K $456.8K
YoY Change -15.99% -16.7% -34.92%
Goodwill $2.348M $2.348M $2.348M
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $55.03K $59.13K $99.58K
YoY Change -35.94% -40.62% -42.94%
Total Long-Term Assets $2.790M $2.788M $2.905M
YoY Change -3.61% -4.02% -9.93%
TOTAL ASSETS
Total Short-Term Assets $12.43M $11.59M $19.07M
Total Long-Term Assets $2.790M $2.788M $2.905M
Total Assets $15.22M $14.37M $21.97M
YoY Change -38.08% -34.58% -11.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $437.4K $471.8K $1.290M
YoY Change -85.38% -63.42% -8.57%
Accrued Expenses $1.400M $1.900M $3.300M
YoY Change -33.33% -42.42% 13.79%
Deferred Revenue
YoY Change
Short-Term Debt $1.329M
YoY Change 54.96%
Long-Term Debt Due $1.000M $1.000M $1.000M
YoY Change 0.0% 0.0% 411.74%
Total Short-Term Liabilities $2.831M $3.465M $7.788M
YoY Change -63.34% -55.5% 46.55%
LONG-TERM LIABILITIES
Long-Term Debt $239.7K $485.4K $1.460M
YoY Change -80.31% -66.76% -34.65%
Other Long-Term Liabilities $572.9K $602.4K $580.2K
YoY Change -0.84% 3.82% 4.36%
Total Long-Term Liabilities $812.6K $1.088M $2.041M
YoY Change -54.74% -46.69% -26.88%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.831M $3.465M $7.788M
Total Long-Term Liabilities $812.6K $1.088M $2.041M
Total Liabilities $4.359M $6.049M $12.03M
YoY Change -61.65% -49.72% 9.53%
SHAREHOLDERS EQUITY
Retained Earnings -$213.0M -$212.6M -$200.7M
YoY Change 5.48% 5.91% 2.22%
Common Stock $224.1M $221.1M $210.9M
YoY Change 4.04% 4.86% 0.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.86M $8.325M $9.943M
YoY Change
Total Liabilities & Shareholders Equity $15.22M $14.37M $21.97M
YoY Change -38.08% -34.58% -11.24%

Cashflow Statement

Concept 2014 Q2 2014 Q1 2013 Q1
OPERATING ACTIVITIES
Net Income -$439.1K -$2.258M -$2.111M
YoY Change -64.48% 6.96% -21.21%
Depreciation, Depletion And Amortization $36.21K $39.94K $52.60K
YoY Change -13.49% -24.07% -41.55%
Cash From Operating Activities -$540.0K -$2.294M $260.4K
YoY Change 10.2% -980.97% -67.09%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K $37.05K $25.47K
YoY Change 0.0% 45.48%
Acquisitions
YoY Change
Other Investing Activities $0.00 $10.00K $0.00
YoY Change -100.0%
Cash From Investing Activities -$40.00K -$29.05K -$25.47K
YoY Change 0.0% 14.06% -137.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.719M $53.41K
YoY Change 4990.87%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.300M $1.377M -$60.36K
YoY Change -33.53% -2382.01% -101.88%
NET CHANGE
Cash From Operating Activities -540.0K -$2.294M $260.4K
Cash From Investing Activities -40.00K -$29.05K -$25.47K
Cash From Financing Activities 2.300M $1.377M -$60.36K
Net Change In Cash 1.720M -$945.7K $174.6K
YoY Change -41.3% -641.71% -95.7%
FREE CASH FLOW
Cash From Operating Activities -$540.0K -$2.294M $260.4K
Capital Expenditures -$40.00K $37.05K $25.47K
Free Cash Flow -$500.0K -$2.331M $234.9K
YoY Change 11.11% -1092.25% -70.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 dei Trading Symbol
TradingSymbol
PIP
CY2014Q1 pip Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1929379 USD
CY2013Q4 pip Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
3182687 USD
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001326190
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54476138 shares
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12600000 shares
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11600000 shares
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
PHARMATHENE, INC
CY2014Q1 us-gaap Assets
Assets
14374221 USD
CY2013Q4 us-gaap Assets
Assets
17139289 USD
CY2014Q1 us-gaap Assets Current
AssetsCurrent
11586064 USD
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2014Q1 pip Billed And Unbilled Accounts Receivable Net
BilledAndUnbilledAccountsReceivableNet
1600000 USD
CY2014Q1 pip Long Term Debt Excluding Discount
LongTermDebtExcludingDiscount
1500004 USD
CY2014Q1 pip Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Annual Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate
0.12 pure
CY2009Q3 pip Warrant Expiration Date
WarrantExpirationDate
2015-01-28
CY2014Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
471803 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1128172 USD
CY2014Q1 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-219367 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-218710 USD
CY2014Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
221125757 USD
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
217877117 USD
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
528878 USD
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
328581 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
14339108 USD
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-946259 USD
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
171894 USD
CY2014Q1 us-gaap Billed Contract Receivables
BilledContractReceivables
USD
CY2013Q4 us-gaap Billed Contract Receivables
BilledContractReceivables
1427113 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9534720 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10480979 USD
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12873411 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12701517 USD
CY2014Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5620128 shares
CY2013Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5620128 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53773705 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52304426 shares
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53773705 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52304426 shares
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
5377 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
5230 USD
CY2014Q1 us-gaap Contracts Revenue
ContractsRevenue
3742525 USD
CY2013Q1 us-gaap Contracts Revenue
ContractsRevenue
6475138 USD
CY2014Q1 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
29705 USD
CY2013Q1 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
9743 USD
CY2012Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
2500000 USD
CY2014Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
1497594 USD
CY2013Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
1740235 USD
CY2013Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
2201390 USD
CY2012Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
1295613 USD
CY2014Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2018 USD
CY2013Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
51663 USD
CY2014Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1495576 USD
CY2013Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1688572 USD
CY2014Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
29705 USD
CY2013Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
9743 USD
CY2014Q1 us-gaap Deferred Revenue
DeferredRevenue
62261 USD
CY2013Q4 us-gaap Deferred Revenue
DeferredRevenue
341723 USD
CY2014Q1 us-gaap Depreciation
Depreciation
39939 USD
CY2013Q1 us-gaap Depreciation
Depreciation
52602 USD
CY2014Q1 us-gaap Derivative Assets
DerivativeAssets
6428787 USD
CY2013Q4 us-gaap Derivative Assets
DerivativeAssets
7928807 USD
CY2014Q1 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
2018 USD
CY2013Q4 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
51663 USD
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2014Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-590 USD
CY2013Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-2678 USD
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2300000 USD
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
CY2014Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
5393 USD
CY2013Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
USD
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2677452 USD
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2279795 USD
CY2014Q1 us-gaap Goodwill
Goodwill
2348453 USD
CY2013Q4 us-gaap Goodwill
Goodwill
2348453 USD
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2228735 USD
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2101642 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-60361 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29050 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25468 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2294064 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
260401 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-656373 USD
CY2013Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-407653 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1427113 USD
CY2013Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-566725 USD
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1274906 USD
CY2013Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
950800 USD
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-279462 USD
CY2013Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-507351 USD
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
178704 USD
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-39486 USD
CY2014Q1 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-549629 USD
CY2013Q1 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-400645 USD
CY2014Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-69872 USD
CY2013Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-99008 USD
CY2014Q1 us-gaap Interest Paid
InterestPaid
43287 USD
CY2013Q1 us-gaap Interest Paid
InterestPaid
67360 USD
CY2014Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
6428787 USD
CY2013Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
7928807 USD
CY2014Q1 us-gaap Liabilities
Liabilities
6048819 USD
CY2013Q4 us-gaap Liabilities
Liabilities
9803577 USD
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14374221 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17139289 USD
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3465457 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6795981 USD
CY2014Q1 us-gaap Long Term Debt
LongTermDebt
1485384 USD
CY2014Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
999996 USD
CY2013Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
999996 USD
CY2014Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
750007 USD
CY2014Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
749997 USD
CY2014Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
485388 USD
CY2013Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
730279 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1377445 USD
CY2014Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
602398 USD
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
588745 USD
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
362 USD
CY2013Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6123 USD
CY2014Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
26591 USD
CY2013Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
32431 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-2258440 USD
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-2111385 USD
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
173131 USD
CY2013Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1010908 USD
CY2014Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
6144391 USD
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
7565872 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2401866 USD
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1090734 USD
CY2014Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
59132 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
65660 USD
CY2014Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-657 USD
CY2013Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1684 USD
CY2014Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2259097 USD
CY2013Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2113069 USD
CY2014Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
USD
CY2013Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
112500 USD
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
37050 USD
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25468 USD
CY2014Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
401448 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
231491 USD
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2719184 USD
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
53413 USD
CY2014Q1 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-1091740 USD
CY2013Q1 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-1274 USD
CY2014Q1 us-gaap Proceeds From Repayments Of Other Long Term Debt
ProceedsFromRepaymentsOfOtherLongTermDebt
-249999 USD
CY2013Q1 us-gaap Proceeds From Repayments Of Other Long Term Debt
ProceedsFromRepaymentsOfOtherLongTermDebt
USD
CY2014Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
8000 USD
CY2013Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
USD
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
380572 USD
CY2014Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
USD
CY2013Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
1091740 USD
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
8325402 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
386068 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3427000 USD
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5233475 USD
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-212586365 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-210327925 USD
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
528878 USD
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
328581 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1217755 shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
60000 shares
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
7335712 USD
CY2014Q1 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
1649896 USD
CY2013Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
2199525 USD
CY2014Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
242641 USD
CY2013Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-905777 USD
CY2014Q1 us-gaap Use Of Estimates
UseOfEstimates
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <em>Use of Estimates</em></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period.&nbsp;&nbsp;Our unaudited condensed consolidated financial statements include significant estimates for our share-based compensation and the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <!--EndFragment--></div> </div>
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53044119 shares
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
48359181 shares

Files In Submission

Name View Source Status
0001144204-14-028677-index-headers.html Edgar Link pending
0001144204-14-028677-index.html Edgar Link pending
0001144204-14-028677.txt Edgar Link pending
0001144204-14-028677-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
pip-20140331.xml Edgar Link completed
pip-20140331.xsd Edgar Link pending
pip-20140331_cal.xml Edgar Link unprocessable
pip-20140331_def.xml Edgar Link unprocessable
pip-20140331_lab.xml Edgar Link unprocessable
pip-20140331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v376166_10q.htm Edgar Link pending
v376166_ex31-1.htm Edgar Link pending
v376166_ex31-2.htm Edgar Link pending
v376166_ex32-1.htm Edgar Link pending
v376166_ex32-2.htm Edgar Link pending